Near Infrared Fluorescence Imaging for Bladder Cancer Detection

• Status: Completed
• Trial end date: 2018-07-25
• Target enrollment: 0
• Participant gender: All

Summary

The primary outcome of this study is to determine the minimal dwell time needed for adequate detection of hexaminolevinulate HCL avid tumors using protoporphyrin IX (PpIX) near infrared fluorescence (NIRF).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Edward Messing
• Collaborator: Imagin Medical
• Treatments: Aminolevulinic Acid

Criteria

Inclusion Criteria:

• Diagnosis of bladder mass on office cystoscopy suspicious for malignancy, either newly diagnosed or a recurrent tumor.

• Planned transurethral resection of bladder tumor in the operating room.

• Ability to give informed consent.

• Willing to spend time for the study

• Men or women (age 18 or older)

• Any racial or ethnic origin

Exclusion Criteria:

• Pregnancy

• Nursing mother

• Diagnosis of porphyria

• Gross hematuria

• BCG immunotherapy or intravesical chemotherapy within the past 90 days

• Known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid